SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ed Offstein who started this subject8/7/2000 10:05:04 AM
From: nigel bates  Read Replies (1) of 2240
 
From the FT -

"A US biotechnology company will on Monday mark a breakthrough in research productivity by announcing it has successfully slashed the time it took to bring a drug from initial research to clinical trial.
Medarex will say that a drug it has developed for prostate cancer has gone into the first phase of clinical trials after just a year of research. Traditionally, drug development can take up to five years.
The company is using human antibody technology that is also being developed by pharmaceutical companies Novartis and Johnson & Johnson, as well as the biotech groups Immunex and Amgen.
The company says it hopes to use the technology to develop about 12 drugs a year...."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News